US 12,202,843 B2
Muscarinic receptor agonists
Miles Stuart Congreve, Cambridge (GB); Giles Albert Brown, Cambridge (GB); Benjamin Gerald Tehan, Cambridge (GB); Mark Pickworth, Cambridge (GB); and Julie Elaine Cansfield, Cambridge (GB)
Assigned to Nxera Pharma UK Limited, Cambridge (GB)
Filed by Nxera Pharma UK Limited, Cambridge (GB)
Filed on Jun. 11, 2021, as Appl. No. 17/345,557.
Application 17/345,557 is a continuation of application No. 16/584,185, filed on Sep. 26, 2019, granted, now 11,034,704.
Application 16/584,185 is a continuation of application No. 15/987,506, filed on May 23, 2018, granted, now 10,428,088, issued on Oct. 1, 2019.
Application 15/987,506 is a continuation of application No. 15/126,935, granted, now 10,030,035, issued on Jul. 24, 2018, previously published as PCT/GB2015/050807, filed on Mar. 19, 2015.
Claims priority of application No. 1404922 (GB), filed on Mar. 19, 2014.
Prior Publication US 2022/0048928 A1, Feb. 17, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 519/00 (2006.01); A61K 31/438 (2006.01); A61K 31/439 (2006.01); A61P 25/00 (2006.01); A61P 25/18 (2006.01); A61P 25/28 (2006.01); C07D 471/10 (2006.01); C07D 498/10 (2006.01)
CPC C07D 519/00 (2013.01) [A61K 31/438 (2013.01); A61K 31/439 (2013.01); A61P 25/00 (2018.01); A61P 25/18 (2018.01); A61P 25/28 (2018.01); C07D 471/10 (2013.01); C07D 498/10 (2013.01)] 18 Claims
 
1. A compound, which is:

OG Complex Work Unit Chemistry
or a salt thereof.